

# Hwai-I Yang

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4039867/publications.pdf>

Version: 2024-02-01

227  
papers

16,534  
citations

36299

51  
h-index

15265

126  
g-index

231  
all docs

231  
docs citations

231  
times ranked

12653  
citing authors

#	ARTICLE	IF	CITATIONS
1	Risk of Hepatocellular Carcinoma Across a Biological Gradient of Serum Hepatitis B Virus DNA Level. JAMA - Journal of the American Medical Association, 2006, 295, 65.	7.4	2,679
2	Predicting Cirrhosis Risk Based on the Level of Circulating Hepatitis B Viral Load. Gastroenterology, 2006, 130, 678-686.	1.3	1,405
3	Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. The Lancet Gastroenterology and Hepatology, 2018, 3, 383-403.	8.1	1,241
4	Hepatitis B e Antigen and the Risk of Hepatocellular Carcinoma. New England Journal of Medicine, 2002, 347, 168-174.	27.0	1,170
5	Associations Between Hepatitis B Virus Genotype and Mutants and the Risk of Hepatocellular Carcinoma. Journal of the National Cancer Institute, 2008, 100, 1134-1143.	6.3	549
6	Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): development and validation of a predictive score. Lancet Oncology, The, 2011, 12, 568-574.	10.7	541
7	Metabolic Factors and Risk of Hepatocellular Carcinoma by Chronic Hepatitis B/C Infection: A Follow-up Study in Taiwan. Gastroenterology, 2008, 135, 111-121.	1.3	492
8	Chronic Hepatitis C Virus Infection Increases Mortality From Hepatic and Extrahepatic Diseases: A Community-Based Long-Term Prospective Study. Journal of Infectious Diseases, 2012, 206, 469-477.	4.0	465
9	Serologic Markers of Epstein-Barr Virus Infection and Nasopharyngeal Carcinoma in Taiwanese Men. New England Journal of Medicine, 2001, 345, 1877-1882.	27.0	423
10	Hepatitis B virus DNA levels and outcomes in chronic hepatitis B. Hepatology, 2009, 49, S72-S84.	7.3	298
11	Carriers of Inactive Hepatitis B Virus Are Still at Risk for Hepatocellular Carcinoma and Liver-Related Death. Gastroenterology, 2010, 138, 1747-1754.e1.	1.3	289
12	Prediction models of long-term Cirrhosis and hepatocellular carcinoma risk in chronic hepatitis B patients: Risk scores integrating host and virus profiles. Hepatology, 2013, 58, 546-554.	7.3	271
13	Nomograms for Risk of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B Virus Infection. Journal of Clinical Oncology, 2010, 28, 2437-2444.	1.6	249
14	Natural history of chronic hepatitis B REVEALed. Journal of Gastroenterology and Hepatology (Australia), 2011, 26, 628-638.	2.8	237
15	Incidence and Determinants of Spontaneous Hepatitis B Surface Antigen Seroclearance: A Community-Based Follow-Up Study. Gastroenterology, 2010, 139, 474-482.	1.3	232
16	Changes in Serum Levels of HBV DNA and Alanine Aminotransferase Determine Risk for Hepatocellular Carcinoma. Gastroenterology, 2011, 141, 1240-1248.e2.	1.3	219
17	Risk and Predictors of Mortality Associated With Chronic Hepatitis B Infection. Clinical Gastroenterology and Hepatology, 2007, 5, 921-931.	4.4	197
18	Lifetime Risk and Sex Difference of Hepatocellular Carcinoma Among Patients With Chronic Hepatitis B and C. Journal of Clinical Oncology, 2011, 29, 3643-3650.	1.6	187

#	ARTICLE	IF	CITATIONS
19	Long-Term Outcomes in Hepatitis B: The REVEAL-HBV Study. <i>Clinics in Liver Disease</i> , 2007, 11, 797-816.	2.1	176
20	Synergism Between Obesity and Alcohol in Increasing the Risk of Hepatocellular Carcinoma: A Prospective Cohort Study. <i>American Journal of Epidemiology</i> , 2013, 177, 333-342.	3.4	175
21	Predicting Hepatocellular Carcinoma by Detection of Aberrant Promoter Methylation in Serum DNA. <i>Clinical Cancer Research</i> , 2007, 13, 2378-2384.	7.0	164
22	Factors Associated With Rates of HBsAg Seroclearance in Adults With Chronic HBV Infection: A Systematic Review and Meta-analysis. <i>Gastroenterology</i> , 2019, 156, 635-646.e9.	1.3	162
23	Spontaneous seroclearance of hepatitis B seromarkers and subsequent risk of hepatocellular carcinoma. <i>Gut</i> , 2014, 63, 1648-1657.	12.1	161
24	Hepatitis C Virus Seromarkers and Subsequent Risk of Hepatocellular Carcinoma: Long-Term Predictors From a Community-Based Cohort Study. <i>Journal of Clinical Oncology</i> , 2010, 28, 4587-4593.	1.6	150
25	Risk of hepatocellular carcinoma and habits of alcohol drinking, betel quid chewing and cigarette smoking: a cohort of 2416 HBsAg-seropositive and 9421 HBsAg-seronegative male residents in Taiwan. <i>Cancer Causes and Control</i> , 2003, 14, 241-250.	1.8	136
26	Hepatitis C Virus Infection and Increased Risk of Cerebrovascular Disease. <i>Stroke</i> , 2010, 41, 2894-2900.	2.0	134
27	Epidemiology and natural history of hepatitis C virus infection. <i>World Journal of Gastroenterology</i> , 2014, 20, 9270-80.	3.3	131
28	Fine Particle Pollution, Alanine Transaminase, and Liver Cancer: A Taiwanese Prospective Cohort Study (REVEAL-HBV). <i>Journal of the National Cancer Institute</i> , 2016, 108, .	6.3	113
29	External Validation of Fatty Liver Index for Identifying Ultrasonographic Fatty Liver in a Large-Scale Cross-Sectional Study in Taiwan. <i>PLoS ONE</i> , 2015, 10, e0120443.	2.5	105
30	Aflatoxin B1 Exposure, Hepatitis B Virus Infection, and Hepatocellular Carcinoma in Taiwan. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2009, 18, 846-853.	2.5	103
31	Serum Levels of Hepatitis B Surface Antigen and DNA Can Predict Inactive Carriers With Low Risk of Disease Progression. <i>Hepatology</i> , 2016, 64, 381-389.	7.3	103
32	Natural history of chronic hepatitis B: what exactly has REVEAL Revealed?. <i>Liver International</i> , 2012, 32, 1333-1341.	3.9	99
33	The rs2296651 (S267F) variant on NTCP ( <i>SLC10A1</i> ) is inversely associated with chronic hepatitis B and progression to cirrhosis and hepatocellular carcinoma in patients with chronic hepatitis B. <i>Gut</i> , 2016, 65, 1514-1521.	12.1	94
34	Significant reduction in end-stage liver diseases burden through the national viral hepatitis therapy program in Taiwan. <i>Hepatology</i> , 2015, 61, 1154-1162.	7.3	90
35	Aflatoxin B <sub>1</sub> exposure increases the risk of cirrhosis and hepatocellular carcinoma in chronic hepatitis B virus carriers. <i>International Journal of Cancer</i> , 2017, 141, 711-720.	5.1	86
36	Causal Mediation Analysis of Survival Outcome with Multiple Mediators. <i>Epidemiology</i> , 2017, 28, 370-378.	2.7	85

#	ARTICLE	IF	CITATIONS
37	Synergistic Effects of Family History of Hepatocellular Carcinoma and Hepatitis B Virus Infection on Risk for Incident Hepatocellular Carcinoma. <i>Clinical Gastroenterology and Hepatology</i> , 2013, 11, 1636-1645.e3.	4.4	84
38	A predictive scoring system for the seroclearance of HBsAg in HBeAg-seronegative chronic hepatitis B patients with genotype B or C infection. <i>Journal of Hepatology</i> , 2013, 58, 853-860.	3.7	80
39	Risk of pancreatic cancer in chronic hepatitis B virus infection: data from the REVEAL-HBV cohort study. <i>Liver International</i> , 2010, 30, 423-429.	3.9	78
40	R331W Missense Mutation of Oncogene <i>YAP1</i> Is a Germline Risk Allele for Lung Adenocarcinoma With Medical Actionability. <i>Journal of Clinical Oncology</i> , 2015, 33, 2303-2310.	1.6	77
41	Obesity and Alcohol Synergize to Increase the Risk of Incident Hepatocellular Carcinoma in Men. <i>Clinical Gastroenterology and Hepatology</i> , 2010, 8, 891-898.e2.	4.4	76
42	Epidemiology of Virus Infection and Human Cancer. <i>Recent Results in Cancer Research</i> , 2014, 193, 11-32.	1.8	72
43	Reduced Incidence of Hepatocellular Carcinoma in Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis B Treated With Tenofovir—A Propensity Score-Matched Study. <i>Journal of Infectious Diseases</i> , 2019, 219, 10-18.	4.0	72
44	Tenofovir Versus Entecavir for Hepatocellular Carcinoma Prevention in an International Consortium of Chronic Hepatitis B. <i>American Journal of Gastroenterology</i> , 2020, 115, 271-280.	0.4	72
45	Community and personal risk factors for hepatitis C virus infection: a survey of 23 820 residents in Taiwan in 1991-2. <i>Gut</i> , 2011, 60, 688-694.	12.1	66
46	Taiwan consensus statement on the management of chronic hepatitis B. <i>Journal of the Formosan Medical Association</i> , 2019, 118, 7-38.	1.7	64
47	Real-World Effectiveness From the Asia Pacific Rim Liver Consortium for HBV Risk Score for the Prediction of Hepatocellular Carcinoma in Chronic Hepatitis B Patients Treated With Oral Antiviral Therapy. <i>Journal of Infectious Diseases</i> , 2020, 221, 389-399.	4.0	58
48	Hepatitis C virus genotype 1b increases cumulative lifetime risk of hepatocellular carcinoma. <i>International Journal of Cancer</i> , 2014, 135, 1119-1126.	5.1	57
49	Hepatitis C viral load, genotype, and increased risk of developing end-stage renal disease: REVEAL-HCV study. <i>Hepatology</i> , 2017, 66, 784-793.	7.3	57
50	Aflatoxin B1 exposure increases the risk of hepatocellular carcinoma associated with hepatitis C virus infection or alcohol consumption. <i>European Journal of Cancer</i> , 2018, 94, 37-46.	2.8	56
51	Updated thresholds for serum alanine aminotransferase level in a large-scale population study composed of 34 346 subjects. <i>Alimentary Pharmacology and Therapeutics</i> , 2012, 36, 560-568.	3.7	55
52	Association Between Fatty Liver and Cirrhosis, Hepatocellular Carcinoma, and Hepatitis B Surface Antigen Seroclearance in Chronic Hepatitis B. <i>Journal of Infectious Diseases</i> , 2021, 224, 294-302.	4.0	51
53	Preeclampsia and the Risk of Bronchopulmonary Dysplasia in VLBW Infants: A Population Based Study. <i>PLoS ONE</i> , 2013, 8, e75168.	2.5	49
54	Host Genetic Factors Affecting Spontaneous HBsAg Seroclearance in Chronic Hepatitis B Patients. <i>PLoS ONE</i> , 2013, 8, e53008.	2.5	47

#	ARTICLE	IF	CITATIONS
55	Reduction of chronic hepatitis B-related hepatocellular carcinoma with anti-viral therapy, including low risk patients. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 44, 846-855.	3.7	47
56	Natural History and Hepatocellular Carcinoma Risk in Untreated Chronic Hepatitis B Patients With Indeterminate Phase. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 1803-1812.e5.	4.4	46
57	Seropositivity of hepatitis B e antigen and hepatocellular carcinoma. <i>Annals of Medicine</i> , 2004, 36, 215-224.	3.8	44
58	Global DNA methylation levels in white blood cells as a biomarker for hepatocellular carcinoma risk: a nested case-control study. <i>Carcinogenesis</i> , 2012, 33, 1340-1345.	2.8	39
59	Prognostic impact of allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia patients with internal tandem duplication of FLT3. <i>Leukemia Research</i> , 2013, 37, 287-292.	0.8	39
60	Development and Validation of a Clinical Scoring System for Predicting Risk of HCC in Asymptomatic Individuals Seropositive for Anti-HCV Antibodies. <i>PLoS ONE</i> , 2014, 9, e94760.	2.5	39
61	Real-world risk score for hepatocellular carcinoma (RWS-HCC): a clinically practical risk predictor for HCC in chronic hepatitis B. <i>Gut</i> , 2016, 65, 887-888.	12.1	39
62	Hepatitis B e Antigen and the Risk of Hepatocellular Carcinoma. <i>New England Journal of Medicine</i> , 2002, 347, 1721-1722.	27.0	38
63	Urinary 15-F 2t -isoprostane, aflatoxin B 1 exposure and hepatitis B virus infection and hepatocellular carcinoma in Taiwan. <i>Carcinogenesis</i> , 2008, 29, 971-976.	2.8	38
64	HCC risk post-SVR with DAAs in East Asians: findings from the REAL-C cohort. <i>Hepatology International</i> , 2020, 14, 1023-1033.	4.2	38
65	Association between obesity, hypertriglyceridemia and low hepatitis B viral load. <i>International Journal of Obesity</i> , 2013, 37, 410-415.	3.4	37
66	Plasma DNA methylation marker and hepatocellular carcinoma risk prediction model for the general population. <i>Carcinogenesis</i> , 2017, 38, 1021-1028.	2.8	37
67	Polycyclic aromatic hydrocarbon- and aflatoxin-albumin adducts, hepatitis B virus infection and hepatocellular carcinoma in Taiwan. <i>Cancer Letters</i> , 2007, 252, 104-114.	7.2	36
68	Chronic hepatitis C virus infection and the risk for diabetes: a community-based prospective study. <i>Liver International</i> , 2017, 37, 179-186.	3.9	36
69	211 G to A Variation of UDP-Glucuronosyl Transferase 1A1 Gene and Neonatal Breastfeeding Jaundice. <i>Pediatric Research</i> , 2011, 69, 170-174.	2.3	35
70	Lower liver cancer risk with antiviral therapy in chronic hepatitis B patients with normal to minimally elevated ALT and no cirrhosis. <i>Medicine (United States)</i> , 2016, 95, e4433.	1.0	35
71	Genetic Factors That Affect Spontaneous Clearance of Hepatitis C or B Virus, Response to Treatment, and Disease Progression. <i>Gastroenterology</i> , 2019, 156, 400-417.	1.3	35
72	Predictability of Liver-Related Seromarkers for the Risk of Hepatocellular Carcinoma in Chronic Hepatitis B Patients. <i>PLoS ONE</i> , 2013, 8, e61448.	2.5	34

#	ARTICLE	IF	CITATIONS
73	High hepatitis C viral load and genotype 2 are strong predictors of chronic kidney disease. <i>Kidney International</i> , 2017, 92, 703-709.	5.2	34
74	Estimating the Incidence and Prevalence of Chronic Hepatitis C Infection in Taiwan Using Back Projection. <i>Value in Health Regional Issues</i> , 2014, 3, 5-11.	1.2	33
75	Human leukocyte antigen variants and risk of hepatocellular carcinoma modified by hepatitis C virus genotypes: A genome-wide association study. <i>Hepatology</i> , 2018, 67, 651-661.	7.3	32
76	Urinary 8-oxodeoxyguanosine, aflatoxin B1 exposure and hepatitis B virus infection and hepatocellular carcinoma in Taiwan. <i>Carcinogenesis</i> , 2006, 28, 995-999.	2.8	31
77	Incidence and Determinants of Spontaneous Seroclearance of Hepatitis B e Antigen and DNA in Patients With Chronic Hepatitis B. <i>Clinical Gastroenterology and Hepatology</i> , 2012, 10, 527-534.e2.	4.4	31
78	Global DNA methylation in a population with aflatoxin B <sub>1</sub> exposure. <i>Epigenetics</i> , 2013, 8, 962-969.	2.7	30
79	Hepatitis C Virus Cure Rates Are Reduced in Patients With Active but Not Inactive Hepatocellular Carcinoma: A Practice Implication. <i>Clinical Infectious Diseases</i> , 2020, 71, 2840-2848.	5.8	30
80	Preeclampsia and Retinopathy of Prematurity in Very-Low-Birth-Weight Infants: A Population-Based Study. <i>PLoS ONE</i> , 2015, 10, e0143248.	2.5	29
81	Distinct seromarkers predict different milestones of chronic hepatitis B progression. <i>Hepatology</i> , 2014, 60, 77-86.	7.3	28
82	Prediagnostic concentrations of circulating bile acids and hepatocellular carcinoma risk: REVEAL-HBV and HCV studies. <i>International Journal of Cancer</i> , 2020, 147, 2743-2753.	5.1	28
83	The case for simplifying and using absolute targets for viral hepatitis elimination goals. <i>Journal of Viral Hepatitis</i> , 2021, 28, 12-19.	2.0	28
84	Lifetime risk of distinct upper aerodigestive tract cancers and consumption of alcohol, betel and cigarette. <i>International Journal of Cancer</i> , 2014, 135, 1480-1486.	5.1	27
85	Alcohol Drinking Mediates the Association between Polymorphisms of ADH1B and ALDH2 and Hepatitis B-Related Hepatocellular Carcinoma. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2016, 25, 693-699.	2.5	27
86	Direct-acting antivirals in East Asian hepatitis C patients: real-world experience from the REAL-C Consortium. <i>Hepatology International</i> , 2019, 13, 587-598.	4.2	27
87	Association of Maternal Preeclampsia with Neonatal Respiratory Distress Syndrome in Very-Low-Birth-Weight Infants. <i>Scientific Reports</i> , 2019, 9, 13212.	3.3	27
88	Hepatitis B Core-Related Antigen to Indicate High Viral Load: Systematic Review and Meta-Analysis of 10,397 Individual Participants. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 46-60.e8.	4.4	27
89	Chronic hepatitis B infection and risk of atherosclerosis-related mortality: A 17-year follow-up study based on 22,472 residents in Taiwan. <i>Atherosclerosis</i> , 2010, 211, 624-629.	0.8	26
90	Polymorphisms near the IFNL3 Gene Associated with HCV RNA Spontaneous Clearance and Hepatocellular Carcinoma Risk. <i>Scientific Reports</i> , 2015, 5, 17030.	3.3	26

#	ARTICLE	IF	CITATIONS
91	Risk and predictors of hepatocellular carcinoma for chronic hepatitis B patients with newly developed cirrhosis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2016, 31, 1971-1977.	2.8	26
92	Hepatocellular Carcinoma Prediction Models in Chronic Hepatitis B: A Systematic Review of 14 Models and External Validation. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 2499-2513.	4.4	26
93	A hospital-based study of clinical and genetic features of Crohn's disease. <i>Journal of the Formosan Medical Association</i> , 2011, 110, 600-606.	1.7	25
94	Incorporating Serum Level of Hepatitis B Surface Antigen or Omitting Level of Hepatitis B Virus DNA Does not Affect Calculation of Risk for Hepatocellular Carcinoma in Patients Without Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 461-468.e2.	4.4	24
95	Serum Levels of M2BPGi as Short-Term Predictors of Hepatocellular Carcinoma in Untreated Chronic Hepatitis B Patients. <i>Scientific Reports</i> , 2017, 7, 14352.	3.3	24
96	Risk calculators for hepatocellular carcinoma in patients affected with chronic hepatitis B in Asia. <i>World Journal of Gastroenterology</i> , 2014, 20, 6244.	3.3	24
97	Thrombospondin-2 is a Highly Specific Diagnostic Marker and is Associated with Prognosis in Pancreatic Cancer. <i>Annals of Surgical Oncology</i> , 2019, 26, 807-814.	1.5	23
98	SIGLEC-3 (CD33) serves as an immune checkpoint receptor for HBV infection. <i>Journal of Clinical Investigation</i> , 2021, 131, .	8.2	23
99	Plasma Adipokines and Risk of Hepatocellular Carcinoma in Chronic Hepatitis B Virus "Infected Carriers: A Prospective Study in Taiwan. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014, 23, 1659-1671.	2.5	20
100	Residues Comprising the Enhanced Aromatic Sequon Influence Protein N-Glycosylation Efficiency. <i>Journal of the American Chemical Society</i> , 2017, 139, 12947-12955.	13.7	20
101	Level of Hepatitis B (HB) Core Antibody Associates With Seroclearance of HBV DNA and HB Surface Antigen in HB e Antigen-Seronegative Patients. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 172-181.e1.	4.4	20
102	Epidemiology of Virus Infection and Human Cancer. <i>Recent Results in Cancer Research</i> , 2021, 217, 13-45.	1.8	19
103	Predicting Hepatitis B Virus (HBV) Surface Antigen Seroclearance in HBV e Antigen-Negative Patients With Chronic Hepatitis B: External Validation of a Scoring System. <i>Journal of Infectious Diseases</i> , 2015, 211, 1566-1573.	4.0	18
104	Mediation Analysis of Hepatitis B and C in Relation to Hepatocellular Carcinoma Risk. <i>Epidemiology</i> , 2016, 27, 14-20.	2.7	18
105	Performance Metrics for Selecting Single Nucleotide Polymorphisms in Late-onset Alzheimer's Disease. <i>Scientific Reports</i> , 2016, 6, 36155.	3.3	17
106	A multiple mediator analysis approach to quantify the effects of the ADH1B and ALDH2 genes on hepatocellular carcinoma risk. <i>Genetic Epidemiology</i> , 2018, 42, 394-404.	1.3	17
107	Fifteen-Year Population Attributable Fractions and Causal Pies of Risk Factors for Newly Developed Hepatocellular Carcinomas in 11,801 Men in Taiwan. <i>PLoS ONE</i> , 2012, 7, e34779.	2.5	16
108	Clinical Efficacy and Post-Treatment Seromarkers Associated with the Risk of Hepatocellular Carcinoma among Chronic Hepatitis C Patients. <i>Scientific Reports</i> , 2017, 7, 3718.	3.3	16

#	ARTICLE	IF	CITATIONS
109	Heparin at physiological concentration can enhance PEG-free in vitro infection with human hepatitis B virus. <i>Scientific Reports</i> , 2017, 7, 14461.	3.3	16
110	Model to Predict Hyperbilirubinemia in Healthy Term and Near-Term Newborns with Exclusive Breast Feeding. <i>Pediatrics and Neonatology</i> , 2012, 53, 354-358.	0.9	15
111	Incidence, Factors, and Patient-Level Data for Spontaneous HBsAg Seroclearance: A Cohort Study of 11,264 Patients. <i>Clinical and Translational Gastroenterology</i> , 2020, 11, e00196.	2.5	15
112	Patterns of Human Leukocyte Antigen Class I and Class II Associations and Cancer. <i>Cancer Research</i> , 2021, 81, 1148-1152.	0.9	15
113	Risk scores to predict HCC and the benefits of antiviral therapy for CHB patients in gray zone of treatment guidelines. <i>Hepatology International</i> , 2021, 15, 1421-1430.	4.2	15
114	Transition rates to cirrhosis and liver cancer by age, gender, disease and treatment status in Asian chronic hepatitis B patients. <i>Hepatology International</i> , 2021, 15, 71-81.	4.2	14
115	Immunologic markers and risk of hepatocellular carcinoma in hepatitis B virus and hepatitis C virus infected individuals. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 54, 833-842.	3.7	14
116	Serum hepatitis B virus DNA as a predictor of the development of cirrhosis and hepatocellular carcinoma. <i>Current Hepatitis Reports</i> , 2007, 6, 9-16.	0.3	13
117	On identification of agonistic interaction: Hepatitis B and C interaction on hepatocellular carcinoma. <i>Statistics in Medicine</i> , 2019, 38, 2467-2476.	1.6	12
118	Associations between reproductive factors and biliary tract cancers in women from the Biliary Tract Cancers Pooling Project. <i>Journal of Hepatology</i> , 2020, 73, 863-872.	3.7	12
119	Risk of hepatitis C virus related hepatocellular carcinoma between subjects with spontaneous and treatment-induced viral clearance. <i>Oncotarget</i> , 2017, 8, 43925-43933.	1.8	12
120	A 0.33-V, 500-kHz, 3.94- $\mu$ W 40-nm 72-Kb 9T Subthreshold SRAM With Ripple Bit-Line Structure and Negative Bit-Line Write-Assist. <i>IEEE Transactions on Circuits and Systems II: Express Briefs</i> , 2012, 59, 863-867.	3.0	11
121	141 SERIAL MONITORING OF VIRAL LOAD AND SERUM ALANINE AMINOTRANSFERASE LEVEL AND THE RISK OF HEPATOCELLULAR CARCINOMA (HCC): R.E.V.E.A.L.-HBV STUDY UPDATE. <i>Journal of Hepatology</i> , 2008, 48, S61.	3.7	9
122	Characteristics of Patients With Chronic Hepatitis B Virus Infection With Genotype E Predominance in Burkina Faso. <i>Hepatology Communications</i> , 2020, 4, 1781-1792.	4.3	9
123	Genetic susceptibility to hepatocellular carcinoma in chromosome 22q13.31, findings of a genome-wide association study. <i>JGH Open</i> , 2021, 5, 1363-1372.	1.6	9
124	Association Between High Levels of Hepatitis B Core Antibody and Seroclearance of Hepatitis B e Antigen in Individuals With Chronic Hepatitis B Virus Infection. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 1413-1415.	4.4	8
125	The human C-type lectin 18 is a potential biomarker in patients with chronic hepatitis B virus infection. <i>Journal of Biomedical Science</i> , 2018, 25, 59.	7.0	7
126	Interferon Is Superior to Direct Acting Antiviral Therapy in Tertiary Prevention of Early Recurrence of Hepatocellular Carcinoma. <i>Cancers</i> , 2020, 12, 23.	3.7	7



#	ARTICLE	IF	CITATIONS
127	HLA Zygosity Increases Risk of Hepatitis B Virus-Associated Hepatocellular Carcinoma. <i>Journal of Infectious Diseases</i> , 2021, , .	4.0	7
128	Application of Risk Scores for Hepatocellular Carcinoma in Patients with Chronic Hepatitis B: Current Status and Future Perspective. <i>Seminars in Liver Disease</i> , 2021, 41, 285-297.	3.6	7
129	Reproductive and environmental exposures and the breast cancer risk in Taiwanese women. <i>Scientific Reports</i> , 2021, 11, 15656.	3.3	6
130	Telomere Length and Risk of Hepatocellular Carcinoma: A Nested Caseâ€“Control Study in Taiwan Cancer Screening Program Cohort. <i>Anticancer Research</i> , 2017, 37, 637-644.	1.1	6
131	Blood DNA methylation markers in prospectively identified hepatocellular carcinoma cases and controls from Taiwan. <i>World Journal of Hepatology</i> , 2016, 8, 301.	2.0	6
132	Incidence of hepatocellular carcinoma in a community-based Taiwanese population without chronic HBV/HCV infection. <i>JHEP Reports</i> , 2022, 4, 100410.	4.9	6
133	Mediation effect of hepatitis B and C on mortality. <i>European Journal of Epidemiology</i> , 2016, 31, 625-633.	5.7	5
134	Hepatitis B splice variants are strongly associated with and are indeed predictive of hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2018, 68, S474-S475.	3.7	5
135	Association between immunologic markers and cirrhosis in individuals with chronic hepatitis B. <i>Scientific Reports</i> , 2021, 11, 21194.	3.3	5
136	Serum soluble programmed cell death 1 levels predict spontaneous functional cure in inactive carriers with chronic hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 558-567.	3.7	5
137	[222] RISK OF LIVER CIRRHOSIS ASSOCIATED WITH GENOTYPE AND MUTANTS OF HEPATITIS B VIRUS. <i>Journal of Hepatology</i> , 2007, 46, S91-S92.	3.7	4
138	Long-term health outcomes of chronic hepatitis C patients: A review of findings from REVEAL-HCV		

#	ARTICLE	IF	CITATIONS
145	Genetic variants associated with serum alanine aminotransferase levels among patients with hepatitis C virus infection: A genome-wide association study. <i>Journal of Viral Hepatitis</i> , 2021, 28, 1265-1273.	2.0	3
146	Serum HBcrAg and Hepatocellular Carcinoma in a Taiwanese Population Seronegative for HBsAg and Anti-HCV. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 1303-1313.e11.	4.4	3
147	27 Risk of hepatocellular carcinoma associated with genotypes and mutants of hepatitis B virus: A community-based prospective cohort study. <i>Journal of Hepatology</i> , 2006, 44, S13.	3.7	2
148	1050 HEPATITIS C VIRUS INFECTION AND MORTALITY FROM LIVER RELATED DISEASE. <i>Journal of Hepatology</i> , 2010, 52, S406-S407.	3.7	2
149	Three Authors Reply. <i>American Journal of Epidemiology</i> , 2013, 178, 1011-1012.	3.4	2
150	Discrepant range of sPD-1 in different studies of chronic hepatitis B. A letter in response to Soluble programmed death-1 is a useful indicator for inflammatory and fibrosis severity in chronic hepatitis B. <i>Journal of Viral Hepatitis</i> , 2019, 26, 930-930.	2.0	2
151	Lower Risk of Hepatocellular Carcinoma With Tenofovir vs Entecavir in Patients With Chronic Hepatitis B. <i>JAMA Oncology</i> , 2019, 5, 915.	7.1	2
152	Antiviral therapy and hepatocellular carcinoma risk in hepatitis B patients with cirrhosis. <i>European Journal of Gastroenterology and Hepatology</i> , 2020, 32, 1207-1211.	1.6	2
153	Association Between Traffic Count and Cardiovascular Mortality: A Prospective Cohort Study in Taiwan. <i>Journal of Epidemiology</i> , 2021, 31, 343-349.	2.4	2
154	Development and Validation of a Risk Score for Liver Cirrhosis Prediction in Untreated and Treated Chronic Hepatitis B. <i>Journal of Infectious Diseases</i> , 2021, 223, 139-146.	4.0	2
155	Natural History of HBV Infection in the Community. <i>Molecular and Translational Medicine</i> , 2016, , 249-276.	0.4	2
156	Serum soluble programmed death-1 levels predict the spontaneous HBeAg seroclearance in chronic hepatitis B. <i>Journal of Gastroenterology</i> , 2022, 57, 423-432.	5.1	2
157	406 HEPATITIS C VIRUS INFECTION AND CEREBROVASCULAR DISEASE MORTALITY. <i>Journal of Hepatology</i> , 2009, 50, S153.	3.7	1
158	W1800 Association Between HBV Replication and Serum ALT Changes Is Not Dependent On HBV Genotype and Mutants. <i>Gastroenterology</i> , 2009, 136, A-864.	1.3	1
159	722 INCIDENCE AND DETERMINANTS OF SPONTANEOUS HEPATITIS B SURFACE ANTIGEN SEROCLEARANCE: A COMMUNITY-BASED LONG-TERM FOLLOW-UP STUDY. <i>Journal of Hepatology</i> , 2010, 52, S281.	3.7	1
160	Response to Letter by Lin et al Regarding Article, "Hepatitis C Virus Infection and Increased Risk of Cerebrovascular Disease". <i>Stroke</i> , 2011, 42, .	2.0	1
161	762 CYTOKINE BIOSIGNATURES ASSOCIATED WITH HEPATOCELLULAR CARCINOMA DEVELOPMENT IN PATIENTS WITH CHRONIC HEPATITIS B. <i>Journal of Hepatology</i> , 2012, 56, S299.	3.7	1
162	P668 SERUM INTERLEUKIN 9 LEVEL AS A PREDICTIVE MARKER OF SPONTANEOUS SEROCLEARANCE OF HEPATITIS B SURFACE ANTIGEN IN CHRONIC HEPATITIS B PATIENTS. <i>Journal of Hepatology</i> , 2014, 60, S291.	3.7	1

#	ARTICLE	IF	CITATIONS
163	0016 : Hepatitis B surface antigen and DNA levels can identify inactive carriers and predict lower risk for hepatocellular carcinoma and cirrhosis among genotype B and C chronic hepatitis B carriers. Journal of Hepatology, 2015, 62, S197.	3.7	1
164	Letter: should anti-viral therapy be recommended for individuals chronically infected with hepatitis B virus and at low risk of hepatocellular carcinoma? Authors' reply. Alimentary Pharmacology and Therapeutics, 2017, 45, 182-183.	3.7	1
165	Antiviral Therapy Reduces Hepatocellular Carcinoma Risk in HBV Cirrhosis Patients with Lower Viral Load. Gastroenterology, 2017, 152, S1052-S1053.	1.3	1
166	Response. Journal of the National Cancer Institute, 2017, 109, djw185.	6.3	1
167	Evaluation for the Genetic Association between Store-Operated Calcium Influx Pathway (STIM1 and) Tj ETQq1 1 0.784314 rgBT /Over 2020, 9, 388.	2.8	1
168	Epidemiology and Control of Severe Acute Respiratory Syndrome (SARS) Outbreak in Taiwan. , 2003, , 301-313.		1
169	Epidemiology of Virus Infection and Human Cancer. , 2015, , 23-47.		1
170	5 A community-based randomized trial on hepatocellular carcinoma screening using abdominal ultrasonography and alpha-fetoprotein in Taiwan. Journal of Hepatology, 2006, 44, S4.	3.7	0
171	457 Determinants of hepatitis B viral load and its decline over time: A community-based follow-up study. Journal of Hepatology, 2006, 44, S170.	3.7	0
172	465 Serum alanine aminotransferase level, correlated factors, and risk of liver diseases: A long-term follow-up study. Journal of Hepatology, 2006, 44, S173.	3.7	0
173	489 Predicting liver disease complications (HCC and cirrhosis) in patients with chronic hepatitis B infection using a risk function model: The R.E.V.E.A.L.-HBV study. Journal of Hepatology, 2006, 44, S182.	3.7	0
174	[426] THE ASSOCIATION BETWEEN GENOTYPE AND HEPATITIS B VIRAL LOAD MAY DEPEND ON HBeAg SEROSTATUS: THE R.E.V.E.A.L.-HBV STUDY. Journal of Hepatology, 2007, 46, S163.	3.7	0
175	644 LIVER DISEASE PROGRESSION IN CHRONIC HEPATITIS B INFECTED PERSONS WITH NORMAL SERUM ALANINE AMINO TRANSFERASE LEVEL: UPDATE FROM THE R.E.V.E.A.L.-HBV STUDY. Journal of Hepatology, 2008, 48, S240.	3.7	0
176	656 NEGATIVE CORRELATION BETWEEN HEPATITIS B AND HEPATITIS C VIRAL LOAD IN CO-INFECTED PERSONS. Journal of Hepatology, 2008, 48, S245.	3.7	0
177	384 RISK AND PREDICTORS OF HCC IN PEOPLE LESS THAN 40 YEARS OF AGE: UPDATE FROM THE REVEAL HBV STUDY. Journal of Hepatology, 2009, 50, S146.	3.7	0
178	385 ASSOCIATION BETWEEN HBV REPLICATION AND SERUM ALT CHANGES IS NOT DEPENDENT ON HBV GENOTYPE AND MUTANTS. Journal of Hepatology, 2009, 50, S146.	3.7	0
179	407 HEPATITIS C VIRUS INFECTION AND MORTALITY FROM VARIOUS CANCERS: A COMMUNITY-BASED LONG-TERM FOLLOW-UP STUDY. Journal of Hepatology, 2009, 50, S154.	3.7	0
180	1051 HEPATITIS C VIRUS INFECTION ASSOCIATED WITH THE RISK OF CEREBROVASCULAR DISEASE. Journal of Hepatology, 2010, 52, S407.	3.7	0

#	ARTICLE	IF	CITATIONS
181	117 SEROMARKERS FOR LONG-TERM PREDICTION OF HEPATOCELLULAR CARCINOMA RISK IN PATIENTS WITH CHRONIC HEPATITIS C. <i>Journal of Hepatology</i> , 2010, 52, S52.	3.7	0
182	Risk score for development of HCC: ready for use in practice? – Authors' reply. <i>Lancet Oncology</i> , The, 2011, 12, 518-519.	10.7	0
183	68 SEROCLEARANCE OF HBVDNA IS THE MOST IMPORTANT PREDICTOR FOR THE REDUCED RISK OF HEPATOCELLULAR CARCINOMA: A TIME-DEPENDENT ANALYSIS OF LONG-TERM SERIALY MEASURED BIOMARKERS. <i>Journal of Hepatology</i> , 2011, 54, S31.	3.7	0
184	907 SINGLE NUCLEOTIDE POLYMORPHISMS ASSOCIATED WITH ELEVATED SERUM VIRAL LOAD OF HEPATITIS B VIRUS IN PATIENTS WITH CHRONIC HEPATITIS B: A GENOME-WIDE ASSOCIATION STUDY IN TAIWAN. <i>Journal of Hepatology</i> , 2011, 54, S361.	3.7	0
185	461 INTEGRATING QUANTITATIVE SERUM HBSAG LEVELS INTO RISK SCORES FOR PREDICTING HEPATOCELLULAR CARCINOMA IN CHRONIC HEPATITIS B PATIENTS. <i>Journal of Hepatology</i> , 2012, 56, S182.	3.7	0
186	462 PREDICTION OF LIVER CIRRHOSIS RISK BY LONG-TERM CHANGES IN SERUM LEVELS OF HBV DNA AND ALANINE AMINOTRANSFERASE. <i>Journal of Hepatology</i> , 2012, 56, S183.	3.7	0
187	473 DEVELOPMENT OF PREDICTION MODELS FOR HBV-RELATED LIVER CIRRHOSIS BY INTEGRATING HBV GENOTYPE AND SERUM LEVELS OF HBV DNA AND HBSAG. <i>Journal of Hepatology</i> , 2012, 56, S186-S187.	3.7	0
188	475 DIFFERENCES IN THE ROLE OF QUANTITATIVE HEPATITIS B SURFACE ANTIGEN BETWEEN HBEAG SEROPOSITIVE AND SERONEGATIVE INDIVIDUALS WITH CHRONIC HEPATITIS B. <i>Journal of Hepatology</i> , 2012, 56, S187.	3.7	0
189	730 CONVENTIONAL SEROMARKERS FOR PREDICTION OF HEPATITIS B VIRUS-ASSOCIATED HEPATOCELLULAR CARCINOMA: AN EASY-TO-USE RISK SCORE. <i>Journal of Hepatology</i> , 2012, 56, S288.	3.7	0
190	902 DEVELOPMENT AND VALIDATION OF PREDICTION MODELS FOR RISK OF HEPATOCELLULAR CARCINOMA AMONG HEPATITIS C VIRUS INFECTED PATIENTS. <i>Journal of Hepatology</i> , 2012, 56, S351.	3.7	0
191	1397 SINGLE NUCLEOTIDE POLYMORPHISMS ASSOCIATED WITH SEROCLEARANCE OF HEPATITIS B SURFACE ANTIGEN IN CHRONIC HEPATITIS B PATIENTS WITH SEROCLEARANCE OF HBV DNA. <i>Journal of Hepatology</i> , 2012, 56, S548.	3.7	0
192	687 SERUM IP-10 LEVEL ASSOCIATED WITH HEPATOCELLULAR CARCINOMA DEVELOPMENT IN PATIENTS WITH CHRONIC HEPATITIS B. <i>Journal of Hepatology</i> , 2013, 58, S279.	3.7	0
193	40 SEROCLEARANCE OF HBVDNA PREDICTS SIGNIFICANTLY REDUCED RISK OF HEPATOCELLULAR CARCINOMA AMONG THOSE WITH HIGH VIRAL LOADS: A TIME-DEPENDENT ANALYSIS OF SERIALY MEASURED BIOMARKERS. <i>Journal of Hepatology</i> , 2013, 58, S17-S18.	3.7	0
194	419 QUANTITATIVE SERUM HEPATITIS B SURFACE ANTIGEN IMPROVES PREDICTABILITY OF HBVDNA SEROCLEARANCE BUT NOT HBeAg SEROCLEARANCE IN CHRONIC HEPATITIS B PATIENTS. <i>Journal of Hepatology</i> , 2013, 58, S172.	3.7	0
195	492 HOST GENETIC VARIANTS AROUND IL28A/IL28B ASSOCIATED WITH HCV-RELATED OUTCOMES BASED ON R.E.V.E.A.L.-HCV COHORT. <i>Journal of Hepatology</i> , 2013, 58, S202.	3.7	0
196	469 GENOME-WIDE ASSOCIATION STUDY TO IDENTIFY POTENTIAL SINGLE NUCLEOTIDE POLYMORPHISMS ASSOCIATED WITH SPONTANEOUS HEPATITIS C VIRUS CLEARANCE AMONG CHRONIC HEPATITIS C PATIENTS. <i>Journal of Hepatology</i> , 2013, 58, S192.	3.7	0
197	Predicting clinical outcome in a patient with chronic hepatitis B virus infection. <i>Clinical Liver Disease</i> , 2013, 2, 5-7.	2.1	0
198	P675 RISK PREDICTORS FOR LIVER CANCER AND CIRRHOSIS AMONG CHRONIC HEPATITIS B PATIENTS WITH UNDETECTABLE HEPATITIS B VIRAL LOADS. <i>Journal of Hepatology</i> , 2014, 60, S294.	3.7	0

#	ARTICLE	IF	CITATIONS
199	P676 SIGNIFICANT REDUCTION IN END-STAGE LIVER DISEASE BURDEN THROUGH NATIONAL CHRONIC VIRAL HEPATITIS THERAPY PROGRAM IN TAIWAN. <i>Journal of Hepatology</i> , 2014, 60, S294.	3.7	0
200	P775 HEPATITIS C VIRUS INFECTION AND THE ASSOCIATED RISK FOR DIABETES MELLITUS. <i>Journal of Hepatology</i> , 2014, 60, S328-S329.	3.7	0
201	P674 SERUM LEVELS OF HEPATITIS B SURFACE ANTIGEN PREDICT LONG-TERM TRAJECTORIES OF HEPATITIS B VIRAL LOAD. <i>Journal of Hepatology</i> , 2014, 60, S293-S294.	3.7	0
202	P769 SINGLE NUCLEOTIDE POLYMORPHISMS NEAR IL28B AND IL28A GENES AND RISK OF LIVER CIRRHOSIS AMONG PATIENTS WITH CHRONIC HEPATITIS C VIRUS INFECTION. <i>Journal of Hepatology</i> , 2014, 60, S327.	3.7	0
203	P0358 : Risk predictors of hepatocellular carcinoma among cirrhotic patients chronically infected with hepatitis B. <i>Journal of Hepatology</i> , 2015, 62, S445.	3.7	0
204	Author's response: Hepatitis B virus seromarkers clearance and risk of hepatocellular carcinoma: serious risks of misinterpretation. <i>Gut</i> , 2015, 64, 186.2-187.	12.1	0
205	P0560 : Association of single nucleotide polymorphism rs2296651 in SLC10A1 with hepatocellular carcinoma and liver cirrhosis. <i>Journal of Hepatology</i> , 2015, 62, S525.	3.7	0
206	P0611 : Trajectories of hepatitis B surface antigen and associations with hepatocellular carcinoma, liver cirrhosis, and HBsAg seroclearance among chronic hepatitis B carriers with low viral loads. <i>Journal of Hepatology</i> , 2015, 62, S546.	3.7	0
207	Tu1675 Development and Validation of a Risk Score System Inclusive of Antiviral Therapy for Predicting Liver Cirrhosis Risk in Diverse Patients With Chronic Hepatitis B Infection. <i>Gastroenterology</i> , 2016, 150, S1164.	1.3	0
208	Tu1671 Higher Serum Testosterone Is Associated With Increased Risk of Liver Cirrhosis In Chronic Hepatitis B: The R.E.V.E.A.L.-HBV Study. <i>Gastroenterology</i> , 2016, 150, S1163.	1.3	0
209	Antiviral Therapy for the Prevention of Long-Term Cirrhosis Risk in Patients with Chronic Hepatitis B. <i>Journal of Hepatology</i> , 2016, 64, S591.	3.7	0
210	Serum Levels of Wisteria Floribunda Agglutinin-Positive MAC-2 Binding Protein as Short-Term Predictors of Hepatocellular Carcinoma in Chronic Hepatitis B. <i>Journal of Hepatology</i> , 2016, 64, S363-S364.	3.7	0
211	Development and Validation of a Risk Score System Inclusive of Antiviral Therapy for Predicting Liver Cirrhosis Risk in Diverse Patients with Chronic Hepatitis B Infection. <i>Journal of Hepatology</i> , 2016, 64, S372.	3.7	0
212	The Applicability of Hepatocellular Carcinoma Risk Prediction Scoring System in a us Patient Cohort with Chronic Hepatitis C Infection. <i>Journal of Hepatology</i> , 2016, 64, S621-S622.	3.7	0
213	Sa1539 The Applicability of Hepatocellular Carcinoma Risk Prediction Scoring System in a US Patient Cohort With Chronic Hepatitis C Infection. <i>Gastroenterology</i> , 2016, 150, S1061.	1.3	0
214	Letter: reduction in chronic hepatitis B-related hepatocellular carcinoma with anti-viral therapy, including low-risk patients – more questions than answers. Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 45, 186-187.	3.7	0
215	Elevated serum wisteria floribunda agglutinin-positive mac-2-binding protein levels associated with risks of diabetes and endstage renal diseases among patients with hepatitis C virus infection. <i>Journal of Hepatology</i> , 2017, 66, S713-S714.	3.7	0
216	Human leukocyte antigen and IL28B polymorphisms independently associated with hepatitis C virus RNA spontaneous clearance: a study from REVEAL-HCV cohort. <i>Journal of Hepatology</i> , 2017, 66, S542.	3.7	0

#	ARTICLE	IF	CITATIONS
217	Regional differences in the presentation and management of patients with hepatocellular carcinoma by liver disease etiology. <i>Journal of Hepatology</i> , 2017, 66, S458.	3.7	0
218	Soluble cytotoxic T-lymphocyte-associated antigen-4 and soluble programmed cell death protein-1 are predictive immune checkpoint seromarkers for spontaneous functional cure of chronic hepatitis B with opposite effects. <i>Journal of Hepatology</i> , 2018, 68, S476.	3.7	0
219	Validation of AASLD treatment guideline eligibility based on disease outcomes of large community and clinical cohorts of chronic hepatitis B patients. <i>Journal of Hepatology</i> , 2018, 68, S503.	3.7	0
220	Real-world rates of hepatitis B surface antigen seroclearance in patients with chronic hepatitis B: a systematic review, conventional aggregated data meta-analysis and individual patient data meta-analysis. <i>Journal of Hepatology</i> , 2018, 68, S478-S479.	3.7	0
221	Single-nucleotide polymorphism of rs7944135 (macrophage-expressed gene 1) is associated with hepatitis B surface antigen seroclearance in chronic hepatitis B infection. <i>Medicine (United States)</i> , 2019, 98, e17936.	1.0	0
222	Epidemiology and Natural History of Hepatitis B Virus Infection: Time-Dependent Driving Factors of Chronic Hepatitis B Progression. , 2021, , 143-167.		0
223	Abstract 2747: Plasma DNA methylation marker and hepatocellular carcinoma risk prediction model for the general population. , 2017, , .		0
224	G-Computation to Causal Mediation Analysis With Sequential Multiple Mediatorsâ€”Investigating the Vulnerable Time Window of HBV Activity for the Mechanism of HCV Induced Hepatocellular Carcinoma. <i>Frontiers in Public Health</i> , 2021, 9, 757942.	2.7	0
225	The association between sPD-1 levels versus liver biochemistry and viral markers in chronic hepatitis B patients: a comparative study of different sPD-1 assays. <i>Virology Journal</i> , 2022, 19, 59.	3.4	0
226	Letter: s <sc>PD</sc> â€”1 as a predictor for <sc>HB</sc> s <sc>A</sc> g seroclearanceâ€”shed light on inactive carriers with chronic hepatitis B. Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 1057-1058.	3.7	0
227	Editorial: incorporating liver stiffness to risk scores for HCC in patients with chronic hepatitis B treated with oral antivirals: ready to use or not?. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 753-754.	3.7	0